RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

C. J A Punt, M. J A De Jonge, S. Monfardini, G. Daugaard, W. Fiedler, B. Baron, D. Lacombe, P. Fumoleau

Research output: Contribution to journalArticlepeer-review

Abstract

Camptothecins have shown efficacy in terms of response rate in patients with small cell lung cancer (SCLC). RFS2000 is a new camptothecin derivative, which has shown objective responses in various tumour types. The aim of this phase II study was to determine the objective response rate of RFS2000 in patients with sensitive and refractory SCLC. RFS2000 was given orally at 1.5 mg/m2 per day for five consecutive days (five days on - two days off) on a continuous basis. Patients were evaluated weekly for toxicity and every six weeks for response. Thirty seven patients were included, 36 patients (14 with sensitive and 22 with refractory SCLC) were evaluable for toxicity, and 35 patients were evaluable for response. No objective responses were observed. Toxicity was acceptable, with myelosuppression, nausea/vomiting, and diarrhoea as the main toxicities. RFS2000 therefore has an acceptable toxicity profile but is not active as a single agent in SCLC.

Original languageEnglish
Pages (from-to)1332-1334
Number of pages3
JournalEuropean Journal of Cancer
Volume40
Issue number9
DOIs
Publication statusPublished - Jun 2004

Keywords

  • Chemotherapy
  • EORTC
  • Phase II study
  • RFS2000
  • Rubitecan
  • Small cell lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group'. Together they form a unique fingerprint.

Cite this